Key Takeaways for AbbVie Stock
- Abbvie Inc.’s revenue grew 12% year-over-year to $15 billion in Q1 2026, beating expectations by $300 million.
- Operating income reached $4.82 billion in Q1 2026, up 19% year-over-year.
- Gross profit grew 15% year-over-year, outpacing the 12% top-line gain for the quarter.
- TIKR’s model values ABBV at approximately $349 by December 2030, implying around 53% total return from the current price.
AbbVie Beats Q1 2026 Revenue Estimates as Skyrizi and Rinvoq Power Double-Digit Growth
AbbVie Inc. (ABBV) delivered first-quarter 2026 revenues of $15 billion following its April 29 earnings call, beating Wall Street estimates by $300 million and marking a 12% year-over-year acceleration that signals the Humira loss-of-exclusivity transition is structurally complete.
The quarter’s growth story belongs to Skyrizi, the interleukin-23 inhibitor treating psoriatic disease and inflammatory bowel disease, and Rinvoq, a JAK inhibitor with indications across rheumatology and gastroenterology.
Skyrizi total sales reached $4.5 billion, growing 29% operationally.
Rinvoq posted $2.1 billion, up 20% on the same basis.
CEO Rob Michael emphasized in Q1 earnings that the company is “delivering top-tier growth and continue to strengthen our long-term outlook with pipeline advancements and strategic transactions.”
AbbVie raised full-year adjusted EPS guidance to a range of $14.08 to $14.28, up $0.12 from the prior midpoint.
Full-year revenue guidance was lifted to approximately $67.3 billion.
Neuroscience revenues of nearly $2.9 billion grew 24% operationally, with Vraylar contributing $905 million and Vyalev on track for blockbuster revenue status this year.
At the Goldman Sachs Global Healthcare Conference in June, management said the Street is meaningfully undermodeling both Skyrizi and Rinvoq at their peak, with each franchise expected to exceed current consensus.
AbbVie’s Operating Leverage Is Compounding, But the Margin Gap Reveals the Mechanism
AbbVie’s revenue reached $15 billion in Q1 2026, growing 12% year-over-year.
Gross profit grew 15% year-over-year in the quarter, outpacing the top-line gain by three percentage points.
Gross margin held at 72% in Q1 2026, consistent with the range maintained across the prior seven quarters.
SG&A came in at $3.49 billion, elevated by the acquired IPR&D charges that CFO Scott Reents identified as a 5% drag on the reported operating margin.
Operating income reached $4.82 billion in Q1 2026, growing 19% year-over-year and outpacing revenue growth by seven percentage points.
The GAAP operating margin printed at 32% in Q1 2026, down from the prior quarter’s 34% but above the eight-quarter trough of 29%.
With gross margins locked near 72%, the path to operating margin expansion runs through SG&A discipline as the Skyrizi and Rinvoq revenue base continues to compound.
AbbVie Holds a Structural Operating Margin Lead Over JNJ and PFE, While LLY Pulls Away
AbbVie has maintained GAAP operating margins above 30% across every year in the peer set, posting 35% in fiscal 2025 against Johnson & Johnson’s (JNJ) 28% and Pfizer’s (PFE) 31%.
Pfizer’s operating margin collapsed to 11% in fiscal 2023 under the weight of its COVID portfolio unwind before recovering to 31% in fiscal 2025, a trajectory that illustrates how exposed single-catalyst revenue bases are to margin volatility.
JNJ has held the narrowest range of the group, moving from 27% in fiscal 2021 to 28% in fiscal 2025, a level of margin consistency that reflects the conglomerate’s diversification but limits its operating leverage upside.
Eli Lilly (LLY) is the outlier in the other direction, expanding from 29% in fiscal 2021 to 46% in fiscal 2025 on the back of GLP-1 volume scaling through a relatively fixed cost structure.
AbbVie’s margin of 35% in fiscal 2025 sits above JNJ and PFE but trails LLY by eleven percentage points, a gap that reflects LLY’s revenue scaling at a rate that drops more efficiently to operating income.
The competitive read for the AbbVie thesis is that its current margin level is structurally defensible given Skyrizi and Rinvoq’s compounding revenue base, but closing the gap to LLY requires SG&A discipline to hold even as the company funds its pipeline with acquired IPR&D charges.
Is AbbVie Stock Undervalued in 2026? TIKR’s $349 Model Says the Leverage Has to Hold
TIKR’s model values AbbVie at approximately $349 by December 2030, implying around 53% total return from the current price of approximately $228.
The target requires the gross profit compounding visible in Q1 2026 to translate into operating margin expansion as SG&A normalizes beyond the current IPR&D investment cycle.
Management’s commentary at Goldman Sachs reinforces the revenue side of the equation: consensus is undermodeling Skyrizi and Rinvoq’s peak potential, which is the scaling engine that makes operating leverage credible at the $349 level.
Should You Invest in AbbVie Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABBV stock on TIKR for Free →
What is AbbVie’s full-year 2026 revenue guidance?
Management raised full-year 2026 revenue guidance to approximately $67.3 billion, supported by Skyrizi’s revised global revenue target of $21.6 billion and Rinvoq’s target of $10.2 billion.
What did AbbVie say about Skyrizi and Rinvoq at the Goldman Sachs conference?
CEO Rob Michael said AbbVie expects both franchises to exceed current peak consensus estimates, with each already growing above 20% in their eighth year on market.
